Assignee
RETROTOPE INC
US·17 granted patents·16 pending applications·42 citations·filing 2014–2022
Top patents by PatentIndex Score
33 records- 0196US11447441B2Site-specific isotopic labeling of 1,4-diene systemsRETROTOPE INC·Filed 2021·Granted Sep 20, 2022·3 cites·15 claims
- 0296US11351143B1Methods of treating amyotrophic lateral sclerosisRETROTOPE INC·Filed 2021·Granted Jun 7, 2022·5 cites·4 claims
- 0395US10730821B2Site-specific isotopic labeling of 1,4-diene systemsRETROTOPE INC·Filed 2016·Granted Aug 4, 2020·8 cites·21 claims
- 0493US10577304B2Site-specific isotopic labeling of 1,4-diene systemsRETROTOPE INC·Filed 2018·Granted Mar 3, 2020·5 cites·13 claims
- 0593US10015979B2Isotopically modified compounds and their use as food supplementsRETROTOPE INC·Filed 2017·Granted Jul 10, 2018·10 cites·20 claims
- 0691USRE49238EAlleviating oxidative stress disorders with PUFA derivativesRETROTOPE INC·Filed 2020·Granted Oct 11, 2022·2 cites·28 claims
- 0789US11491130B2Methods of treating amyotrophic lateral sclerosisRETROTOPE INC·Filed 2021·Granted Nov 8, 2022·1 cites·14 claims
- 0886US11453637B2Site-specific isotopic labeling of 1,4-diene systemsRETROTOPE INC·Filed 2019·Granted Sep 27, 2022·3 cites·19 claims
- 0985US11241409B2Neurodegenerative disorders and muscle diseases implicating PUFAsRETROTOPE INC·Filed 2018·Granted Feb 8, 2022·1 cites·8 claims
- 1082US9616042B2Isotopically modified compounds and their use as food supplementsRETROTOPE INC·Filed 2016·Granted Apr 11, 2017·2 cites·22 claims
- 1178US10918126B2Isotopically modified compounds and their use as food supplementsRETROTOPE INC·Filed 2018·Granted Feb 16, 2021·1 cites·22 claims
- 1278US2021331998A1Site-specific isotopic labeling of 1,4-diene systemsRETROTOPE INC·Filed 2021·Application pending·0 cites
- 1375US11510888B2Alleviating oxidative stress disorders with PUFA derivativesRETROTOPE INC·Filed 2019·Granted Nov 29, 2022·0 cites·6 claims
- 1475US2022378734A1Neurodegenerative disorders and muscle diseases implicating pufasRETROTOPE INC·Filed 2022·Application pending·0 cites
- 1572US11166930B2Isotopically modified components and therapeutic uses thereofRETROTOPE INC·Filed 2017·Granted Nov 9, 2021·1 cites·27 claims
- 1672US2022304968A1Oxidative retinal diseasesRETROTOPE INC·Filed 2022·Application pending·0 cites
- 1770US11510889B2Methods for inhibiting the progression of neurodegenerative diseasesRETROTOPE INC·Filed 2021·Granted Nov 29, 2022·0 cites·18 claims
- 1869US11285125B2Oxidative retinal diseasesRETROTOPE INC·Filed 2018·Granted Mar 29, 2022·0 cites·25 claims
- 1969US2022401399A1Methods of treating amyotrophic lateral sclerosisRETROTOPE INC·Filed 2022·Application pending·0 cites
- 2067US9320289B2Isotopically modified compounds and their use as food supplementsRETROTOPE INC·Filed 2014·Granted Apr 26, 2016·0 cites·18 claims
- 2164US2023100267A1Inhibition of cellular dysfunction and cell death with deuterated polyunsaturated fatty acidsRETROTOPE INC·Filed 2021·Application pending·0 cites
- 2264US2022133668A1Isotopically modified components and therapeutic uses thereofRETROTOPE INC·Filed 2021·Application pending·0 cites
- 2363US2021244637A1Deuterated polyunsaturated fatty acids or esters thereof for cosmetic applicationsRETROTOPE INC·Filed 2021·Application pending·0 cites
- 2463US2021251933A1Methods for treating tauopathyRETROTOPE INC·Filed 2021·Application pending·0 cites
- 2560US2019054052A1Alleviating oxidative stress disorders with pufa derivativesRETROTOPE INC·Filed 2018·Application pending·0 cites
- 2658US2024091189A1Methods for Assessing a Patient's Response to Treatment of a Neurodegenerative Disease with Deuterated Arachidonic AcidRETROTOPE INC·Filed 2022·Application pending·0 cites
- 2757US8901102B2Therapeutic substances that modulate genome methylationRETROTOPE INC·Filed 2014·Granted Dec 2, 2014·0 cites·10 claims
- 2857US2019231729A1Disorders implicating pufa oxidationRETROTOPE INC·Filed 2018·Application pending·0 cites
- 2955US2022009950A1Deuterated compounds, compositions, and methods of useRETROTOPE INC·Filed 2019·Application pending·0 cites
- 3053US2021069144A1Isotopically modified composition and therapeutic uses thereofRETROTOPE INC·Filed 2019·Application pending·0 cites
- 3151US2019046644A1Impaired energy processing disorders and mitochondrial deficiencyRETROTOPE INC·Filed 2018·Application pending·0 cites
- 3243US2021252173A1Stabilized polyunsaturated compounds and uses thereofRETROTOPE INC·Filed 2019·Application pending·0 cites
- 3341US2019084900A1Isotopically modified composition and therapeutic uses thereofRETROTOPE INC·Filed 2017·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →